Anidulafungin: a new echinocandin for candidal infections

Authors: de la Torre, Pola; Reboli, Annette C

Source: Expert Review of Anti-Infective Therapy, Volume 5, Number 1, February 2007 , pp. 45-52(8)

Publisher: Expert Reviews

Key:

- Free Content

- New Content

- Subscribed Content

- Free Trial Content

Abstract:

Anidulafungin, a new echinocandin, has recently been approved for the treatment of esophageal candidiasis, candidemia and other forms of invasive candidiasis, such as peritonitis and intra-abdominal abscesses in non-neutropenic patients. It is fungicidal against Candida spp. including those that are azole- and polyene-resistant and fungistatic against Aspergillus spp. Owing to its poor oral bioavailability it can only be administered intravenously. Its pharmacokinetics allow for once-daily dosing and a steady state concentration is easily achieved on day 2 following a loading dose of double the maintenance dose on day 1. It does not need adjustment for hepatic or renal insufficiency; there are no known drug interactions and it has a favorable tolerability profile. Its mechanism of action, which differs from other classes of antifungals, should prevent cross-resistance with azoles and polyenes.

Keywords: anidulafungin; candidemia; echinocandin; esophageal candidiasis

Document Type: Research article

DOI: 10.1586/14787210.5.1.45

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$73.00 plus tax Refund Policy